Jakob Loven, Ph.D., joined Nextech Invest as Partner in 2017 from Third Rock Ventures, where Jakob focused on new company formation in the areas of oncology and emerging technologies. Dr. Loven also served on the firm’s scientific ideation team, overseeing several early-stage projects and leading efforts to transform emerging areas of science into innovative drug discovery companies with unique scientific platforms. Jakob brings to Nextech the passion of a serial entrepreneur. While at Third Rock, Jakob launched Relay Therapeutics in Cambridge Massachusetts, which was selected as one of Fiercebiotech’s Fierce 15 in 2017. Prior to Relay, Jakob was a Founding Scientist of Syros Pharmaceuticals (NASDAQ: SYRS), which was founded on his co-discoveries in gene regulation sciences and technologies, and had its initial public offering in July 2016. Jakob holds a BA in Biomedical Sciences from the Anglia Ruskin University of Cambridge, earned his Ph.D. in Medical Sciences from Karolinska Institutet, and conducted his postdoctoral fellowship at the Whitehead Institute for Biomedical Research. During his appointment at the Whitehead Institute, Jakob pioneered the field of gene regulation research through numerous scientific findings, authoring several high-impact journal articles. At Nextech, Jakob manages our investments in Autolus, A2 Biotherapeutics, and Arvinas.
Mr. Loven is responsible for the following Nextech portfolio companies:
A2 Biotherapeutics, Arvinas
Portfolio companies Mr. Loven has been involved with previously: